Compare Shionogi & Co., Ltd. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 13.50%
- Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 55.35
2
Positive results in Jun 26
3
With ROE of 12.84%, it has a very attractive valuation with a 1.65 Price to Book Value
4
Majority shareholders : FIIs
Stock DNA
Pharmaceuticals & Biotechnology
JPY 2,558,582 Million (Large Cap)
13.00
NA
0.00%
-0.03
12.22%
1.52
Revenue and Profits:
Net Sales:
163,310 Million
(Quarterly Results - Jun 2026)
Net Profit:
97,718 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.82%
0%
-10.82%
6 Months
-17.18%
0%
-17.18%
1 Year
7.13%
0%
7.13%
2 Years
-55.17%
0%
-55.17%
3 Years
-53.95%
0%
-53.95%
4 Years
-58.4%
0%
-58.4%
5 Years
-53.46%
0%
-53.46%
Shionogi & Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.96%
EBIT Growth (5y)
9.00%
EBIT to Interest (avg)
43.84
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
0.31
Tax Ratio
13.81%
Dividend Payout Ratio
29.45%
Pledged Shares
0
Institutional Holding
0.05%
ROCE (avg)
16.22%
ROE (avg)
13.50%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
1.65
EV to EBIT
14.15
EV to EBITDA
12.49
EV to Capital Employed
1.76
EV to Sales
4.92
PEG Ratio
0.80
Dividend Yield
NA
ROCE (Latest)
12.41%
ROE (Latest)
12.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.05%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
163,310.00
138,993.00
17.50%
Operating Profit (PBDIT) excl Other Income
60,632.00
38,504.00
57.47%
Interest
5,322.00
2,838.00
87.53%
Exceptional Items
0.00
0.00
Consolidate Net Profit
97,718.00
47,702.00
104.85%
Operating Profit Margin (Excl OI)
243.40%
199.60%
4.38%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 17.50% vs -5.91% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 104.85% vs -36.12% in Mar 2026
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
499,677.00
438,268.00
14.01%
Operating Profit (PBDIT) excl Other Income
188,348.00
180,712.00
4.23%
Interest
1,284.00
1,646.00
-21.99%
Exceptional Items
-37,382.00
-7,698.00
-385.61%
Consolidate Net Profit
205,914.00
169,534.00
21.46%
Operating Profit Margin (Excl OI)
323.00%
364.60%
-4.16%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 14.01% vs 0.73% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 21.46% vs 5.58% in Mar 2025
About Shionogi & Co., Ltd. 
Shionogi & Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






